Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 178

Results For "PLI"

2945 News Found

FDA accepts submission of olaparib in combination with abiraterone and prednisone for prostate cancer
Drug Approval | August 17, 2022

FDA accepts submission of olaparib in combination with abiraterone and prednisone for prostate cancer

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations


Lupin receives approval from U.S. FDA for Meclizine Hydrochloride Tablets USP
Drug Approval | August 16, 2022

Lupin receives approval from U.S. FDA for Meclizine Hydrochloride Tablets USP

Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.


Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222
Diagnostic Center | August 16, 2022

Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222

WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".


Fish & Richardson secures win for Exela Pharma Sciences in ELCYS patent infringement litigation
News | August 16, 2022

Fish & Richardson secures win for Exela Pharma Sciences in ELCYS patent infringement litigation

ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions


QIAGEN launches syndromic test for QIAstat-Dx device to combat Monkeypox health emergency
News | August 16, 2022

QIAGEN launches syndromic test for QIAstat-Dx device to combat Monkeypox health emergency

QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms


Yashoda Hospitals successfully performs bariatric surgery
Hospitals | August 15, 2022

Yashoda Hospitals successfully performs bariatric surgery

Man lost 54 Kgs in 6 months with MGB procedure


ENHERTU delays disease progression in DESTINYBreast02 Phase 3 Trial
Diagnostic Center | August 15, 2022

ENHERTU delays disease progression in DESTINYBreast02 Phase 3 Trial

Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients


Lupin receives USFDA approval for Meclizine Hydrochloride Tablets USP
Drug Approval | August 13, 2022

Lupin receives USFDA approval for Meclizine Hydrochloride Tablets USP

The product will be manufactured at Lupin’s facility in Goa, India.


Vascular experts establish appropriate use of IVUS in peripheral interventions
News | August 13, 2022

Vascular experts establish appropriate use of IVUS in peripheral interventions

Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions


Roche gets USFDA approval of Xofluza to treat influenza in children
Drug Approval | August 13, 2022

Roche gets USFDA approval of Xofluza to treat influenza in children

Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age